 low-dos chemotherapi central nervou system prophylaxi zidovudin mainten aids-rel lymphoma prospect multi-institut trial low-dos multiag chemotherapi central nervou system prophylaxi antiretrovir therapi increas efficaci risk intercurr infect patient malign lymphoma immunodefici syndrom aid phase II prospect clinic trial median follow-up month eight univers hospit context aid clinic trial unit nation institut allergi infecti diseas forty-two patient aids-rel malign lymphoma evalu toxic assess respons low-dos modif m-bacod regimen day cyclophosphamid IV doxorubicin IV vincristin sulfat IV bleomycin IV dexamethason day methotrex IV day leucovorin rescu intrathec cytosin arabinosid mg day radiat therapi helmet field central nervou system involv zidovudin month complet cycl chemotherapi main outcom respons rate number opportunist infect respons rate complet respons complet respons relaps none central nervou system opportunist infect treatment median durat surviv patient month month patient evalu respons month patient complet respons concentr cell histori prior aid bone marrow involv stage IV diseas decreas surviv low-dos chemotherapi central nervou system prophylaxi zidovudin mainten durabl remiss aids-rel lymphoma opportunist infect prior report